PPD DEVELOPMENT LP - BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Key Details
Description
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Context & Analysis
On Nov 12, 2025, Department of Health and Human Services obligated $117,399,278 to PPD DEVELOPMENT LP for barda will implement a randomized, double-blind, placebo-controlled, multicenter phase 2 trial in the us to evaluate the safety and efficacy of novel host-directed therapeutic candidates in hospitaliz…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus incentive fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in WILMINGTON, NC. The contract is scheduled through Sep 30, 2030. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Market context
- Recompete outlook
- Ends Sep 30, 2030, in 47 months. Recompete signal as of Oct 26, 2026: 50/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed, with 1 offer. 96% of 222 awards in this market (Department of Health and Human Services awards in NAICS 541714 over the last 3 years) were competed; median 1 offers.
- Award size
- At $117.4M, this award is larger than 19 in 20 of the 212 priced Department of Health and Human Services awards in NAICS 541714 over the last 3 years (median $1.2M).
- Incumbent at this agency
- PPD DEVELOPMENT LP has 11 other awards from Department of Health and Human Services, totalling $229.5M, 2021–2026.
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541714 over the last 3 years.
- TECHNICAL RESOURCES INTERNATIONAL, INC. — 4 awards, $379.6M
- ALLUCENT GOVERNMENT SERVICES (US) LLC — 2 awards, $373.2M
- ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. — 4 awards, $342.2M
- PARATEK PHARMACEUTICALS, INC — 1 award, $265.3M
- GENENTECH INC — 1 award, $243.7M
Computed from USAspending award data on Oct 26, 2026.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.